PolyMedix, Inc. (PYMX.OB)


PolyMedix is a publicly traded biotechnology company that is developing novel, synthetic small molecule compounds that mimic the activity of large natural proteins; compounds referred to as biomimetics. PolyMedix focuses on creating new therapeutic drugs to meet unmet medical needs for treatment of serious, life threatening, acute disorders, including PolyMedix's initial programs involving new drug treatments for infectious diseases and acute cardiovascular disorders. Using its proprietary computational drug design technology, PolyMedix has created novel antibiotic and anticoagulant antagonist (Heparin and Low Molecular Weight Heparin, or LMWH) drug compounds intended for human therapeutic use. PolyMedix is also developing polymeric formulations of its antibiotic compounds as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. PolyMedix is headquartered in Radnor, Pennsylvania.

Contact Information

3701 Market Street
Suite 442
Philadelphia, PA 19104

tel: 2159666227


Investor Relations



Exchange: OTCBB
Industry: Biotechnology
Market Cap: $25.9M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.